Latest Agios Pharmaceuticals Inc (AGIO) Headlines $AGIO
Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation
Business Wire - Wed Mar 19, 7:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:48AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session,reversing the recent trend for AGIO as the stock is now up around 37.7% in the past one-month time frame.
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Why Pixelworks, Energy Recovery, and Agios Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 4:15PM CST
It was yet another day of mixed economic data for the S&P 500 , which tugged and pulled the broad-based index to a fresh all-time high. Adding the most fuel to the fire today was the weekly initial jobless claims report, which showed a ...
Why Agios Pharmaceuticals, Inc. Shares Skyrocketed
Alex Planes, The Motley Fool - Motley Fool - Thu Mar 06, 12:51PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals, Inc. began the...
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:30AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2013.
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
Agios Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
Business Wire - Thu Feb 27, 4:24PM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the company will host a conference call and live audio webcast on Thursday, March 6, 2014, at 8:30 a.m. EST to report its fourth quarter and full year 2013 financial results and discuss recent business activities.
Agios Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 7:02AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:50PM EST at the Boston Marriott Copley Place.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Agios Pharmaceuticals to Present at the 2014 Leerink Swann Global Healthcare Conference
Business Wire - Thu Feb 06, 7:00AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the 2014 Leerink Swann Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 p.m. EST at the Waldorf Astoria Hotel in New York City.
Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration
Business Wire - Mon Feb 03, 7:00AM CST
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced today that it has elected to retain the United States development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 25, 8:00AM CST
While the overall hot streak for health care continues unabated despite the latest signs of a pullback in the broader market, not every health-care stock is prospering. Here are three of this week's most horrendous performers. Another "no" Amarin ...
Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation
Business Wire - Wed Mar 19, 7:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:48AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session,reversing the recent trend for AGIO as the stock is now up around 37.7% in the past one-month time frame.
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Why Pixelworks, Energy Recovery, and Agios Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 4:15PM CST
It was yet another day of mixed economic data for the S&P 500 , which tugged and pulled the broad-based index to a fresh all-time high. Adding the most fuel to the fire today was the weekly initial jobless claims report, which showed a ...
Why Agios Pharmaceuticals, Inc. Shares Skyrocketed
Alex Planes, The Motley Fool - Motley Fool - Thu Mar 06, 12:51PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals, Inc. began the...
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:30AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2013.
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
Agios Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
Business Wire - Thu Feb 27, 4:24PM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the company will host a conference call and live audio webcast on Thursday, March 6, 2014, at 8:30 a.m. EST to report its fourth quarter and full year 2013 financial results and discuss recent business activities.
Agios Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 7:02AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:50PM EST at the Boston Marriott Copley Place.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Myeloproliferative Disorders - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 11, 9:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rhjv83/myeloproliferative) has announced the addition of the "Myeloproliferative Disorders - Pipeline Review, H2 2013" report to their offering. 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Scope - A snapshot of the global therapeutic scenario for Myeloproliferative Disorders. - A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Myeloproliferative Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Myeloproliferative Disorders - Products under Development by Companies Myeloproliferative Disorders - Products under Investigation by Universities/Institutes Myeloproliferative Disorders - Companies Involved in Therapeutics Development Myeloproliferative Disorders - Therapeutics Assessment Triapine - Drug Profile givinostat - Drug Profile ganetespib - Drug Profile KB-004 - Drug Profile gandotinib - Drug Profile EPZ-5676 - Drug Profile ON-044580 - Drug Profile Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms - Drug Profile Kinase Inhibitors for Oncology - Drug Profile Small Molecule To Inhibit JAK2 For Myeloproliferative Disorder - Drug Profile AG-120 - Drug Profile CPL-407-22 - Drug Profile Jak2 Inhibitors - Drug Profile Featured News & Press Releases Companies Mentioned Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Synta Pharmaceuticals Corp. Italfarmaco S.p.A. Celon Pharma Sp. z o.o. Agios Pharmaceuticals, Inc. Onconova Therapeutics, Inc. KaloBios Pharmaceuticals, Inc. EpiZyme, Inc. For more information visit http://www.researchandmarkets.com/research/rh...liferative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Agios Pharmaceuticals to Present at the 2014 Leerink Swann Global Healthcare Conference
Business Wire - Thu Feb 06, 7:00AM CST
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the 2014 Leerink Swann Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 p.m. EST at the Waldorf Astoria Hotel in New York City.
Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration
Business Wire - Mon Feb 03, 7:00AM CST
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced today that it has elected to retain the United States development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 25, 8:00AM CST
While the overall hot streak for health care continues unabated despite the latest signs of a pullback in the broader market, not every health-care stock is prospering. Here are three of this week's most horrendous performers. Another "no" Amarin ...
